LUCD Stock Overview
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Lucid Diagnostics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.68 |
| 52 Week High | US$1.85 |
| 52 Week Low | US$0.63 |
| Beta | 1.63 |
| 1 Month Change | -31.00% |
| 3 Month Change | -52.23% |
| 1 Year Change | -53.53% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.19% |
Recent News & Updates
Recent updates
We're A Little Worried About Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate
May 09
Lucid Diagnostics (NASDAQ:LUCD) Will Have To Spend Its Cash Wisely
Dec 15Lucid Diagnostics launches stage II lucid test center in California, Texas, Florida, and Ohio
Aug 11We're Keeping An Eye On Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate
Jul 07Shareholder Returns
| LUCD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -14.2% | 1.6% | 1.0% |
| 1Y | -53.5% | -1.4% | 21.9% |
Return vs Industry: LUCD underperformed the US Medical Equipment industry which returned -1.4% over the past year.
Return vs Market: LUCD underperformed the US Market which returned 21.9% over the past year.
Price Volatility
| LUCD volatility | |
|---|---|
| LUCD Average Weekly Movement | 8.9% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LUCD's share price has been volatile over the past 3 months.
Volatility Over Time: LUCD's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 70 | Lishan Aklog | www.luciddx.com |
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.
Lucid Diagnostics Inc. Fundamentals Summary
| LUCD fundamental statistics | |
|---|---|
| Market cap | US$32.96m |
| Earnings (TTM) | -US$52.67m |
| Revenue (TTM) | US$2.43m |
13.6x
P/S Ratio-0.6x
P/E RatioIs LUCD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LUCD income statement (TTM) | |
|---|---|
| Revenue | US$2.43m |
| Cost of Revenue | US$5.98m |
| Gross Profit | -US$3.55m |
| Other Expenses | US$49.12m |
| Earnings | -US$52.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.09 |
| Gross Margin | -146.25% |
| Net Profit Margin | -2,169.11% |
| Debt/Equity Ratio | -603.6% |
How did LUCD perform over the long term?
See historical performance and comparison